Physician profile
Devon Elizabeth Driver
NPI 1821432899
$21,383.51
in general payments reported to CMS, 2019-2025
33 companies · $5,102 in 2025
The $5,102 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,651 · 2022: $4,055 · 2023: $5,298 · 2024: $3,277 · 2025: $5,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $1,140 · Education: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,170.32 |
| Consulting Fee | $1,140.00 |
| Education | $367.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,436.44 | 2021-2025 | |
| Ucb, INC. | $2,252.82 | 2021-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $1,807.10 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $1,738.60 | 2021-2025 | Ilumya, Blu-U, Odomzo |
| Mayne Pharma Commercial LLC | $1,543.15 | 2021-2025 | |
| Janssen Biotech, INC. | $1,342.01 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Amgen INC. | $1,162.42 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $1,115.28 | 2021-2025 | |
| Incyte Corporation | $867.10 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $736.23 | 2022-2024 | Vtama |
| Pfizer INC. | $726.22 | 2021-2025 | |
| Genzyme Corporation | $580.88 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $576.07 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $567.57 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $528.71 | 2021-2025 | Taltz, Olumiant, Ebglyss |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $528.42 | 2021-2025 | Jublia, Cabtreo, Siliq |
| Leo Pharma INC. | $518.80 | 2021-2025 | Adbry, Anzupgo, Spevigo |
| Janssen Scientific Affairs, LLC | $507.08 | 2021-2023 | Tremfya |
| Vyne Pharmaceuticals INC. | $392.49 | 2021 | |
| Almirall LLC | $375.22 | 2021-2024 | Seysara, Klisyri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.36 | 2022-2025 | Spevigo, Cyltezo |
| Galderma Laboratories, L.P. | $203.89 | 2021-2025 | Nemluvio |
| Medimetriks Pharmaceuticals, INC. | $171.94 | 2021-2023 | Neo-Synalar |
| Epi Health, LLC | $156.88 | 2021-2022 | |
| Organon LLC | $109.63 | 2025 | Vtama, Hadlima |
| Regeneron Pharmaceuticals, INC. | $32.81 | 2023 | Dupixent |
| Journey Medical Corporation | $32.37 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $26.94 | 2022-2023 | Valchlor |
| Botanix Sb INC | $20.50 | 2025 | Sofdra |
| Cipher Pharmaceuticals US LLC | $19.27 | 2025 | Natroba, Spinosad |
| Sebela Pharmaceuticals INC. | $19.12 | 2023 | Naftin |
| Nabriva Therapeutics, Plc | $16.26 | 2021 | |
| Biofrontera INC. | $15.93 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devon Driver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.